Society for Immunotherapy of Cancer

Amgen’s first-in-class oncolytic drug OK’d by FDA

Wednesday, October 28, 2015

The FDA has approved Amgen’s Biologics License Application for IMLYGIC (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after initial surgery. [Read More]